Strong Outlook for Cartesian Therapeutics: FDA SPA Agreement and Positive Phase 2b Results Boost Confidence in Descartes-08
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated ...